DNp73 a matter of cancer: Mechanisms and clinical implications

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1785, Issue 2, 2008, Pages 207-216

  Buhlmann, Sven ^a   Pützer, Brigitte M ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Cancer; Differentiation; DNp73; Oncogene; Tumor suppressor pathways; Tumorigenesis

Indexed keywords

PROTEIN DNP73; PROTEIN P73; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CANCER INHIBITION; CARCINOGENESIS; DISEASE SEVERITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEINS;

EID: 41949088521     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2008.01.002     Document Type: Review

References (82)

1. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., Ferrara P., McKeon F., and Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
2. Moll U.M., and Slade N. p63 and p73: roles in development and tumor formation. Mol. Cancer Res. 2 (2004) 371-386
3. Liu G., Nozell S., Xiao H., and Chen X. DeltaNp73beta is active in transactivation and growth suppression. Mol. Cell. Biol. 24 (2004) 487-501
4. Sayan A.E., Roperch J.P., Sayan B.S., Rossi M., Pinkoski M.J., Knight R.A., Willis A.E., and Melino G. Generation of DeltaTAp73 proteins by translation from a putative internal ribosome entry site. Ann. N.Y. Acad. Sci. 1095 (2007) 315-324
5. Muttray A.F., Cox R.L., Reinisch C.L., and Baldwin S.A. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues. Mar. Biotechnol. (NY). 9 (2007) 217-230
6. Stiewe T., and Putzer B.M. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat. Genet. 26 (2000) 464-469
7. Irwin M., Marin M.C., Phillips A.C., Seelan R.S., Smith D.I., Liu W., Flores E.R., Tsai K.Y., Jacks T., Vousden K.H., and Kaelin Jr. W.G. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407 (2000) 645-648
8. Seelan R.S., Irwin M., van der Stoop P., Qian C., Kaelin Jr. W.G., and Liu W. The human p73 promoter: characterization and identification of functional E2F binding sites. Neoplasia 4 (2002) 195-203
9. Nakagawa T., Takahashi M., Ozaki T., Watanabe K., Hayashi S., Hosoda M., Todo S., and Nakagawara A. Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells. Cancer Lett. 197 (2003) 105-109
10. Vossio S., Palescandolo E., Pediconi N., Moretti F., Balsano C., Levrero M., and Costanzo A. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 21 (2002) 3796-3803
11. Kartasheva N.N., Contente A., Lenz-Stoppler C., Roth J., and Dobbelstein M. p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene 21 (2002) 4715-4727
12. Grob T.J., Novak U., Maisse C., Barcaroli D., Luthi A.U., Pirnia F., Hugli B., Graber H.U., De Laurenzi V., Fey M.F., Melino G., and Tobler A. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 8 (2001) 1213-1223
13. Fontemaggi G., Gurtner A., Strano S., Higashi Y., Sacchi A., Piaggio G., and Blandino G. The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. Mol. Cell. Biol. 21 (2001) 8461-8470
14. Dominguez G., Pena C., Silva J., Garcia J.M., Garcia V., Rodriguez R., Cantos B., Citores M.J., Espana P., and Bonilla F. The presence of an intronic deletion in p73 and high levels of ZEB1 alter the TAp73/DeltaTAp73 ratio in colorectal carcinomas. J. Pathol. 210 (2006) 390-397
15. Yu J., Baron V., Mercola D., Mustelin T., and Adamson E.D. A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Cell Death Differ. 14 (2007) 436-446
16. Jost C.A., Marin M.C., and Kaelin Jr. W.G. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389 (1997) 191-194
17. Yang A., and McKeon F. P63 and P73: P53 mimics, menaces and more. Nat. Rev. Mol. Cell. Biol. 1 (2000) 199-207
18. Ishida S., Yamashita T., Nakaya U., and Tokino T. Adenovirus-mediated transfer of p53-related genes induces apoptosis of human cancer cells. Jpn. J. Cancer Res. 91 (2000) 174-180
19. Zaika A.I., Slade N., Erster S.H., Sansome C., Joseph T.W., Pearl M., Chalas E., and Moll U.M. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196 (2002) 765-780
20. Stiewe T., Theseling C.C., and Putzer B.M. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J. Biol. Chem. 277 (2002) 14177-14185
21. Pozniak C.D., Radinovic S., Yang A., McKeon F., Kaplan D.R., and Miller F.D. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289 (2000) 304-306
22. Lee A.F., Ho D.K., Zanassi P., Walsh G.S., Kaplan D.R., and Miller F.D. Evidence that DeltaNp73 promotes neuronal survival by p53-dependent and p53-independent mechanisms. J. Neurosci. 24 (2004) 9174-9184
23. Nakagawa T., Takahashi M., Ozaki T., Watanabe Ki K., Todo S., Mizuguchi H., Hayakawa T., and Nakagawara A. Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol. Cell. Biol. 22 (2002) 2575-2585
24. Ishimoto O., Kawahara C., Enjo K., Obinata M., Nukiwa T., and Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 62 (2002) 636-641
25. Simoes-Wust A.P., Sigrist B., Belyanskaya L., Hopkins Donaldson S., Stahel R.A., and Zangemeister-Wittke U. DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells. J. Neurooncol. 72 (2005) 29-34
26. Racek T., Mise N., Li Z., Stoll A., and Putzer B.M. C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (hTERT) promoter. J. Biol. Chem. 280 (2005) 40402-40405
27. Beitzinger M., Oswald C., Beinoraviciute-Kellner R., and Stiewe T. Regulation of telomerase activity by the p53 family member p73. Oncogene 25 (2006) 813-826
28. Kartasheva N.N., Lenz-Bauer C., Hartmann O., Schafer H., Eilers M., and Dobbelstein M. DeltaNp73 can modulate the expression of various genes in a p53-independent fashion. Oncogene 22 (2003) 8246-8254
29. Tanaka Y., Kameoka M., Itaya A., Ota K., and Yoshihara K. Regulation of HSF1-responsive gene expression by N-terminal truncated form of p73alpha. Biochem. Biophys. Res. Commun. 317 (2004) 865-872
30. Tanaka Y., Ota K., Kameoka M., Itaya A., and Yoshihara K. Up-regulation of NFkappaB-responsive gene expression by DeltaNp73alpha in p53 null cells. Exp. Cell Res. 312 (2006) 1254-1264
31. Stiewe T., Stanelle J., Theseling C.C., Pollmeier B., Beitzinger M., and Putzer B.M. Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73. J. Biol. Chem. 278 (2003) 14230-14236
32. Gong J.G., Costanzo A., Yang H.Q., Melino G., Kaelin Jr. W.G., Levrero M., and Wang J.Y. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399 (1999) 806-809
33. Yuan Z.M., Shioya H., Ishiko T., Sun X., Gu J., Huang Y.Y., Lu H., Kharbanda S., Weichselbaum R., and Kufe D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399 (1999) 814-817
34. Chen X., Zheng Y., Zhu J., Jiang J., and Wang J. p73 is transcriptionally regulated by DNA damage, p53, and p73. Oncogene 20 (2001) 769-774
35. Irwin M.S., Kondo K., Marin M.C., Cheng L.S., Hahn W.C., and Kaelin Jr. W.G. Chemosensitivity linked to p73 function. Cancer Cell 3 (2003) 403-410
36. Bergamaschi D., Gasco M., Hiller L., Sullivan A., Syed N., Trigiante G., Yulug I., Merlano M., Numico G., Comino A., Attard M., Reelfs O., Gusterson B., Bell A.K., Heath V., Tavassoli M., Farrell P.J., Smith P., Lu X., and Crook T. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3 (2003) 387-402
37. Müller M., Schilling T., Sayan A.E., Kairat A., Lorenz K., Schulze-Bergkamen H., Oren M., Koch A., Tannapfel A., Stremmel W., Melino G., and Krammer P.H. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ. 12 (2005) 1564-1577
38. Stiewe T., Zimmermann S., Frilling A., Esche H., and Putzer B.M. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res. 62 (2002) 3598-3602
39. Maisse C., Munarriz E., Barcaroli D., Melino G., and De Laurenzi V. DNA damage induces the rapid and selective degradation of the DeltaNp73 isoform, allowing apoptosis to occur. Cell Death Differ. 11 (2004) 685-687
40. Rossi M., De Laurenzi V., Munarriz E., Green D.R., Liu Y.C., Vousden K.H., Cesareni G., and Melino G. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J. 24 (2005) 836-848
41. Vayssade M., Haddada H., Faridoni-Laurens L., Tourpin S., Valent A., Benard J., and Ahomadegbe J.C. P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells. Int. J. Cancer 116 (2005) 860-869
42. Sabatino M.A., Previdi S., and Broggini M. In vivo evaluation of the role of DNp73alpha protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs. Int. J. Cancer 120 (2007) 506-513
43. Putzer B.M., Tuve S., Tannapfel A., and Stiewe T. Increased DeltaN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived DeltaN¢-p73 transcript. Cell Death Differ. 10 (2003) 612-614
44. Tuve S., Racek T., Niemetz A., Schultz J., Soengas M.S., and Putzer B.M. Adenovirus-mediated TA-p73beta gene transfer increases chemosensitivity of human malignant melanomas. Apoptosis 11 (2006) 235-243
45. Petrenko O., Zaika A., and Moll U.M. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol. Cell. Biol. 23 (2003) 5540-5555
46. Huttinger-Kirchhof N., Cam H., Griesmann H., Hofmann L., Beitzinger M., and Stiewe T. The p53 family inhibitor DeltaNp73 interferes with multiple developmental programs. Cell Death Differ. 13 (2006) 174-177
47. Erster S., Palacios G., Rosenquist T., Chang C., and Moll U.M. Deregulated expression of DeltaNp73alpha causes early embryonic lethality. Cell Death Differ. 13 (2006) 170-173
48. Cam H., Griesmann H., Beitzinger M., Hofmann L., Beinoraviciute-Kellner R., Sauer M., Huttinger-Kirchhof N., Oswald C., Friedl P., Gattenlohner S., Burek C., Rosenwald A., and Stiewe T. p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 10 (2006) 281-293
49. Tannapfel A., John K., Mise N., Schmidt A., Buhlmann S., Ibrahim S.M., and Putzer B.M. Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor deltaNp73. Carcinogenesis 29 (2008) 211-218
50. Kovalev S., Marchenko N., Swendeman S., LaQuaglia M., and Moll U.M. Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ. 9 (1998) 897-903
51. Dominguez G., Garcia J.M., Peňa C., Silva J., García V., Martínez L., Maximiano C., Gómez M.E., Rivera J.A., García-Andrade C., and Bonilla F. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J. Clin. Oncol. 24 (2006) 105-115
52. Uramoto H., Sugio K., Oyama T., Nakata S., Ono K., Nozoe T., and Yasumoto K. Expression of the p53 family in lung cancer. Anticancer Res. 26 (2006) 1785-1790
53. Uramoto H., Sugio K., Oyama T., Nakata S., Ono K., Morita M., Funa K., and Yasumoto K. Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin. Cancer Res. 10 (2004) 6905-6911
54. Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R., and Vigneri P. p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res. 63 (2003) 5829-5837
55. Ferru A., Denis S., Guilhot J., Gibelin H., Tourani J.M., Kraimps J.L., Larsen C.J., and Karayan-Tapon L. Expression of TAp73 and DeltaNp73 isoform transcripts in thyroid tumours. Eur. J. Surg. Oncol. 32 (2006) 228-230
56. Bozzetti C., Nizzoli R., Musolino A., Martella E.M., Crafa P., Lagrasta C.A., Camisa R., Bonati A., Lunghi P., and Ardizzoni A. p73 and p53 pathway in human breast cancers. J. Clin. Oncol. 25 (2007) 1451-1453
57. Concin N., Hofstetter G., Berger A., Gehmacher A., Reimer D., Watrowski R., Tong D., Schuster E., Hefler L., Heim K., Mueller-Holzner E., Marth C., Moll U.M., Zeimet A.G., and Zeillinger R. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin. Cancer Res. 11 (2005) 8372-8383
58. Liu S.S., Chan K.Y., Cheung A.N., Liao X.Y., Leung T.W., and Ngan H.Y. Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin. Cancer Res. 12 (2006) 3922-3927
59. Becker K., Pancoska P., Concin N., Vanden Heuvel K., Slade N., Fischer M., Chalas E., and Moll U.M. Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers. Int. J. Oncol. 29 (2006) 889-902
60. Guan M., and Chen Y. Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J. Clin. Pathol. 58 (2005) 1175-1179
61. Tuve S., Wagner S.N., Schittek B., and Putzer B.M. Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression. Int. J. Cancer 108 (2004) 162-166
62. Casciano I., Mazzocco K., Boni L., Pagnan G., Banelli B., Allemanni G., Ponzoni M., Tonini G.P., and Romani M. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 9 (2002) 246-251
63. Douc-Rasy S., Barrois M., Echeynne M., Kaghad M., Blanc E., Raguenez G., Goldschneider D., Terrier-Lacombe M.J., Hartmann O., Moll U., Caput D., and Benard J. DeltaN-p73alpha accumulates in human neuroblastic tumors. Am. J. Pathol. 160 (2002) 631-639
64. Stiewe T., Tuve S., Peter M., Tannapfel A., Elmaagacli A.H., and Putzer B.M. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin. Cancer Res. 10 (2004) 626-633
65. Leupin N., Luthi A., Novak U., Grob T.J., Hugli B., Graber H., Fey M.F., and Tobler A. p73 status in B-cell chronic lymphocytic leukaemia. Leuk. Lymphoma 45 (2004) 1205-1207
66. Ito Y., Uramoto H., Funa K., Yoshida H., Jikuzono T., Asahi S., Higashiyama T., Tomoda C., Takamura Y., Miya A., Kobayashi K., Matsuzuka F., Kuma K., and Miyauchi A. Delta Np73 expression in thyroid neoplasms originating from follicular cells. Pathology 38 (2006) 205-209
67. Ng S.W., Lim C.H., Wang C.W., and Chua Y.L. Analysis of p73 in human borderline and invasive ovarian tumor. Jpn. J. Thorac. Cardiovasc. Surg. 54 (2006) 416-419
68. Wager M., Guilhot J., Blanc J.L., Ferrand S., Milin S., Bataille B., Lapierre F., Denis S., Chantereau T., Larsen C.J., and Karayan-Tapon L. Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients. Br. J. Cancer 95 (2006) 1062-1069
69. Concin N., Becker K., Slade N., Erster S., Mueller-Holzner E., Ulmer H., Daxenbichler G., Zeimet A., Zeillinger R., Marth C., and Moll U.M. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res. 64 (2004) 2449-2460
70. O'Nions J., Brooks L.A., Sullivan A., Bell A., Dunne B., Rozycka M., Reddy A., Tidy J.A., Evans D., Farrell P.J., Evans A., Gasco M., Gusterson B., and Crook T. p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. Br. J. Cancer 85 (2001) 1551-1556
71. Dominguez G., Silva J.M., Silva J., Garcia J.M., Sanchez A., Navarro A., Gallego I., Provencio M., Espana P., and Bonilla F. Wild type p73 overexpression and high-grade malignancy in breast cancer. Breast Cancer Res. Treat. 66 (2001) 183-190
72. Rizzo M.G., Giombini E., Diverio D., Vignetti M., Sacchi A., Testa U., Lo-Coco F., and Blandino G. Analysis of p73 expression pattern in acute myeloid leukemias: lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia 18 (2004) 1804-1809
73. Sayan A.E., Sayan B.S., Findikli N., and Ozturk M. Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells. Oncogene 20 (2001) 5111-5117
74. Joo M., Kang Y.K., Kim M.R., Lee H.K., and Jang J.J. Cyclin D1 overexpression in hepatocellular carcinoma. Liver 21 (2001) 89-95
75. De Laurenzi V., Raschella G., Barcaroli D., Annicchiarico-Petruzzelli M., Ranalli M., Catani M.V., Tanno B., Costanzo A., Levrero M., and Melino G. Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J. Biol. Chem. 275 (2000) 15226-15231
76. Koster M.I., and Roop D.R. The role of p63 in development and differentiation of the epidermis. J. Dermatol. Sci. 34 (2004) 3-9
77. Porrello A., Cerone M.A., Coen S., Gurtner A., Fontemaggi G., Cimino L., Piaggio G., Sacchi A., and Soddu S. p53 regulates myogenesis by triggering the differentiation activity of pRb. J. Cell. Biol. 151 (2000) 1295-1304
78. Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A., McKeon F., and Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumour. Nature 404 (2000) 99-103
79. Billon N., Terrinoni A., Jolicoeur C., McCarthy A., Richardson W.D., Melino G., and Raff M. Roles for p53 and p73 during oligodendrocyte development. Development 131 (2004) 1211-1220
80. Zhang J., and Chen X. DeltaNp73 modulates nerve growth factor-mediated neuronal differentiation through repression of TrkA. Mol. Cell. Biol. 27 (2007) 3868-3880
81. Saifudeen Z., Diavolitsis V., Stefkova J., Dipp S., Fan H., and El-Dahr S.S. Spatiotemporal switch from DeltaNp73 to TAp73 isoforms during nephrogenesis: impact on differentiation gene expression. J. Biol. Chem. 280 (2005) 23094-23102
82. Belloni L., Moretti F., Merlo P., Damalas A., Costanzo A., Blandino G., and Levrero M. DNp73alpha protects myogenic cells from apoptosis. Oncogene 25 (2006) 3606-3612